Skip to main content
. 2011;33(2):131–139. doi: 10.5581/1516-8484.20110034

Figure 4.

Figure 4

Dasatinib dose adjustment – neutropenia, febrile neutropenia and thrombocytopenia (G3/4) in the treatment of CML (accelerated and blastic phases) and Ph-positive acute lymphoblastic leukemia(2,28)